<HashMap><database>biostudies-literature</database><scores/><additional><submitter>He X</submitter><funding>Distinguished Young Scholars in Dalian</funding><funding>Natural Science Foundation of Liaoning Province</funding><funding>Liaoning Revitalization Talents Program</funding><pagination>1875</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12521673</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>16(1)</volume><pubmed_abstract>&lt;h4>Backgrounds&lt;/h4>Pancreatic cancer is one of the most common malignancies in the gastrointestinal system, notorious for its high malignancy and low survival rate. Amentoflavone (AMF), an ingredient in various Traditional Chinese Medicines (TCM), possesses anticancer properties. However, the underlying mechanisms of its action remain unclear.  METHODS: Initially, through the application of network pharmacology and molecular docking methodologies, we elucidated the putative core targets and signaling pathways underlying the antineoplastic potential of amentoflavone. Subsequently, we corroborated the therapeutic efficacy and underlying mechanisms of amentoflavone within both in vitro pancreatic cancer cell models and in vivo animal models.&lt;h4>Results&lt;/h4>The key targets of amentoflavone we</pubmed_abstract><journal>Discover oncology</journal><pubmed_title>Network pharmacology and experimental study on the inhibition of glycolysis by amentoflavone in pancreatic cancer.</pubmed_title><pmcid>PMC12521673</pmcid><funding_grant_id>(2022RJ19</funding_grant_id><funding_grant_id>XLYC1907113</funding_grant_id><funding_grant_id>2023010109-JH2/1013</funding_grant_id><pubmed_authors>Choe H</pubmed_authors><pubmed_authors>Chen P</pubmed_authors><pubmed_authors>Ali T</pubmed_authors><pubmed_authors>He X</pubmed_authors><pubmed_authors>Ma J</pubmed_authors><pubmed_authors>Zhang L</pubmed_authors><pubmed_authors>Zhao Z</pubmed_authors><pubmed_authors>Ding K</pubmed_authors><pubmed_authors>Wu X</pubmed_authors></additional><is_claimable>false</is_claimable><name>Network pharmacology and experimental study on the inhibition of glycolysis by amentoflavone in pancreatic cancer.</name><description>&lt;h4>Backgrounds&lt;/h4>Pancreatic cancer is one of the most common malignancies in the gastrointestinal system, notorious for its high malignancy and low survival rate. Amentoflavone (AMF), an ingredient in various Traditional Chinese Medicines (TCM), possesses anticancer properties. However, the underlying mechanisms of its action remain unclear.  METHODS: Initially, through the application of network pharmacology and molecular docking methodologies, we elucidated the putative core targets and signaling pathways underlying the antineoplastic potential of amentoflavone. Subsequently, we corroborated the therapeutic efficacy and underlying mechanisms of amentoflavone within both in vitro pancreatic cancer cell models and in vivo animal models.&lt;h4>Results&lt;/h4>The key targets of amentoflavone we</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Oct</publication><modification>2026-06-04T11:45:36.389Z</modification><creation>2026-05-08T03:10:51.978Z</creation></dates><accession>S-EPMC12521673</accession><cross_references><pubmed>41085927</pubmed><doi>10.1007/s12672-025-03697-4</doi></cross_references></HashMap>